Zurich, June 26, 2018. MetrioPharm AG, a clinical stage pharmaceutical biotech company developing new medications against chronic immune disorders, today announced that clinical Phase IIa data obtained from patients with moderate to severe plaque psoriasis will be presented at the 5th World Psoriasis & Psoriatic Arthritis Conference (WPPAC) in Stockholm.
The poster presentation details are as follows:
Every three years, the International Federation of Psoriasis Associations (IFPA) organizes the WPPAC, a conference for medical professionals from all over the world to present their latest developments in psoriasis and psoriatic arthritis research.
Psoriasis is a chronic-relapsing, inflammatory autoimmune dermatosis, which is often manifested as plaque psoriasis. A global report published by the world health organization (WHO) in 2016 describes psoriasis as one of the major health burdens worldwide and highlights the need for new, tolerable, and effective medications.
At the WPPAC, MetrioPharm, represented by Dr. Petra Schulz, will present clinical data of the completed Phase IIa psoriasis study. In this randomized, double-blind, parallel, and placebo-controlled trial, 46 patients with moderate to severe plaque psoriasis were treated twice daily with 100 mg MP1032. After only six weeks of treatment, MP1032 reduced the PASI scores by about 28 % in patients who entered the study with moderate psoriasis. Furthermore, the excellent safety profile of MP1032 was confirmed in this trial. Dr. Petra Schulz commented “This makes us look forward to the results of our Phase II study that is currently running in 14 study centers over Germany as well as Poland and is expected to be finalized in the first quarter of 2019.”
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.